Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.
Cell-based immunotherapy, in which antigen-loaded antigen-presenting cells (APC) are used to elicit T cell responses, has become part of the search for alternative cancer and infectious disease treatments. Here, we report on the feasibility of using mRNA-electroporated CD40-activated B cells (CD40-B cells) as alternative APC for the ex vivo induction of antigen-specific CD8(+) T cell responses. The potential of CD40-B cells as APC is reflected in their phenotypic analysis, showing a polyclonal, strongly activated B cell population with high expression of MHC and co-stimulatory molecules. Flow cytometric analysis of EGFP expression 24 h after EGFP mRNA-electroporation showed that CD40-B cells can be RNA transfected with high gene transfer efficiency. No difference in transfection efficiency or postelectroporation viability was observed between CD40-B cells and monocyte-derived dendritic cells (DC). Our first series of experiments show clearly that peptide-pulsed CD40-B cells are able to (re)activate both CD8+ and CD4(+) T cells against influenza and cytomegalovirus (CMV) antigens. To demonstrate the ability of viral antigen mRNA-electroporated CD40-B cells to induce virus-specific CD8+ T cell responses, these antigen-loaded cells were co-cultured in vitro with autologous peripheral blood mononuclear cells (PBMC) for 7 days followed by analysis of T cell antigen-specificity. These experiments show that CD40-B cells electroporated with influenza M1 mRNA or with CMV pp65 mRNA are able to activate antigen-specific interferon (IFN)-gamma-producing CD8(+) T cells. These findings demonstrate that mRNA-electroporated CD40-B cells can be used as alternative APC for the induction of antigen-specific (memory) CD8(+) T cell responses, which might overcome some of the drawbacks inherent to DC immunotherapy protocols.
Van den Bosch
G A
GA
Laboratory of Experimental Hematology, Antwerp University Hospital (UZA), University of Antwerp (UA), Belgium.
Ponsaerts
P
P
Nijs
G
G
Lenjou
M
M
Vanham
G
G
Van Bockstaele
D R
DR
Berneman
Z N
ZN
Van Tendeloo
V F I
VF
D000938:Antigen-Presenting Cells / Q000276:immunology*; D000956:Antigens, Viral / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D019013:CD40 Antigens / Q000276:immunology*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D018929:Cell Culture Techniques; D002460:Cell Line; D003587:Cytomegalovirus / Q000276:immunology; D018274:Electroporation; D049452:Green Fluorescent Proteins / Q000235:genetics; D006650:Histocompatibility Testing; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D008213:Lymphocyte Activation; D012333:RNA, Messenger / Q000032:analysis
D000956:Antigens, Viral; D019013:CD40 Antigens; D012333:RNA, Messenger; D049452:Green Fluorescent Proteins
J Exp Med. 1999 Dec 6;190(11):1669-78
10587357
Nat Med. 2000 Mar;6(3):332-6
10700237
Clin Exp Immunol. 2003 Dec;134(3):378-84
14632740
Nat Immunol. 2004 Jan;5(1):7-10
14699398
Blood. 2004 Mar 15;103(6):2046-54
14630810
J Infect Dis. 2004 Mar 15;189(6):971-83
14999599
J Immunol. 2004 Jun 1;172(11):6649-57
15153480
Proc Natl Acad Sci U S A. 1973 Jan;70(1):190-4
4346033
Adv Exp Med Biol. 1993;329:1-9
8379358
J Exp Med. 1996 Aug 1;184(2):465-72
8760800
J Immunol Methods. 1996 Sep 27;196(2):137-51
8841452
Immunol Today. 1997 Mar;18(3):102-4
9078679
J Clin Invest. 1997 Dec 1;100(11):2757-65
9389740
Nat Med. 1998 Mar;4(3):328-32
9500607
Nature. 1998 Mar 19;392(6673):245-52
9521319
Nat Biotechnol. 1998 Apr;16(4):364-9
9555728
J Virol. 2000 Oct;74(20):9762-5
11000251
Gene Ther. 2000 Dec;7(23):2028-35
11175315
Blood. 2001 Jul 1;98(1):49-56
11418462
Cancer Res. 2001 Sep 1;61(17):6451-8
11522640
J Clin Invest. 2002 Feb;109(3):409-17
11828001
Curr Opin Mol Ther. 2002 Feb;4(1):76-9
11883698
Blood. 2002 May 1;99(9):3319-25
11964299
Leukemia. 2002 Jul;16(7):1324-30
12094257
J Immunother. 2002 Jul-Aug;25(4):289-303
12142552
J Immunol. 2002 Aug 15;169(4):1676-82
12165486
J Immunol. 2002 Aug 15;169(4):2164-71
12165546
Hum Immunol. 2003 Apr;64(4):440-52
12651070
Cancer Res. 2003 Jun 1;63(11):2836-43
12782589
Blood. 2003 Oct 1;102(7):2338-44
12714511
Nat Med. 2003 Nov;9(11):1377-82
14528297